Persistent Cancer Cells: The Deadly Survivors

被引:196
作者
Shen, Shensi [1 ]
Vagner, Stephan [3 ,4 ,5 ]
Robert, Caroline [1 ,2 ,6 ]
机构
[1] Gustave Roussy Canc Campus, INSERM U981, Villejuif, France
[2] Univ Paris Sud, Univ Paris Saclay, Le Kremlin Bicetre, France
[3] PSL Res Univ, Inst Curie, INSERM U1278, CNRS,UMR3348, Orsay, France
[4] Univ Paris Sud, Univ Paris Saclay, INSERM U1278, CNRS,UMR3348, Orsay, France
[5] Equipe Labellisee Ligue Natl Canc, Orsay, France
[6] Gustave Roussy Canc Campus, Dermatooncol, Villejuif, France
关键词
STRESS-INDUCED MUTAGENESIS; FATTY-ACID OXIDATION; MESENCHYMAL TRANSITION; METABOLIC SYMBIOSIS; TARGETED THERAPY; PROSTATE-CANCER; TUMOR DORMANCY; LUNG-CANCER; RESISTANCE; MELANOMA;
D O I
10.1016/j.cell.2020.10.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenotypic plasticity. Mechanisms that underlie their persistence offer highly coveted and sought-after therapeutic targets, and include diverse epigenetic, transcriptional, and translational regulatory processes, as well as complex cell-cell interactions. Although the successful clinical targeting of persistent cancer cells remains to be realized, immense progress has been made in understanding their persistence, yielding promising preclinical results.
引用
收藏
页码:860 / 874
页数:15
相关论文
共 126 条
[71]  
Nouri M, 2017, ONCOTARGET, V8, P18949, DOI 10.18632/oncotarget.14850
[72]   Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer [J].
Ohlund, Daniel ;
Handly-Santana, Abram ;
Biffi, Giulia ;
Elyada, Ela ;
Almeida, Ana S. ;
Ponz-Sarvise, Mariano ;
Corbo, Vincenzo ;
Oni, Tobiloba E. ;
Hearn, Stephen A. ;
Lee, Eun Jung ;
Chio, Iok In Christine ;
Hwang, Chang-Il ;
Tiriac, Herve ;
Baker, Lindsey A. ;
Engle, Dannielle D. ;
Feig, Christine ;
Kultti, Anne ;
Egeblad, Mikala ;
Fearon, Douglas T. ;
Crawford, James M. ;
Clevers, Hans ;
Park, Youngkyu ;
Tuveson, David A. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2017, 214 (03) :579-596
[73]   A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion [J].
Overholtzer, Michael ;
Mailleux, Arnaud A. ;
Mouneimne, Ghassan ;
Normand, Guillaume ;
Schnitt, Stuart J. ;
King, Randall W. ;
Cibas, Edmund S. ;
Brugge, Joan S. .
CELL, 2007, 131 (05) :966-979
[74]   Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing [J].
Paek, Andrew L. ;
Liu, Julia C. ;
Loewer, Alexander ;
Forrester, William C. ;
Lahav, Galit .
CELL, 2016, 165 (03) :631-642
[75]   Liquid biopsy and minimal residual disease - latest advances and implications for cure [J].
Pantel, Klaus ;
Alix-Panabieres, Catherine .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (07) :409-424
[76]   Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer [J].
Park, Jun Hyoung ;
Vithayathil, Sajna ;
Kumar, Santosh ;
Sung, Pi-Lin ;
Dobrolecki, Lacey Elizabeth ;
Putluri, Vasanta ;
Bhat, Vadiraja B. ;
Bhowmik, Salil Kumar ;
Gupta, Vineet ;
Arora, Kavisha ;
Wu, Danli ;
Tsouko, Efrosini ;
Zhang, Yiqun ;
Maity, Suman ;
Donti, Taraka R. ;
Graham, Brett H. ;
Frigo, Daniel E. ;
Coarfa, Cristian ;
Yotnda, Patricia ;
Putluri, Nagireddy ;
Sreekumar, Arun ;
Lewis, Michael T. ;
Creighton, Chad J. ;
Wong, Lee-Jun C. ;
Kaipparettu, Benny Abraham .
CELL REPORTS, 2016, 14 (09) :2154-2165
[77]   Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy [J].
Pisarsky, Laura ;
Bill, Ruben ;
Fagiani, Ernesta ;
Dimeloe, Sarah ;
Goosen, Ryan William ;
Hagmann, Jorg ;
Hess, Christoph ;
Christofori, Gerhard .
CELL REPORTS, 2016, 15 (06) :1161-1174
[78]   Non-Darwinian dynamics in therapy-induced cancer drug resistance [J].
Pisco, Angela Oliveira ;
Brock, Amy ;
Zhou, Joseph ;
Moor, Andreas ;
Mojtahedi, Mitra ;
Jackson, Dean ;
Huang, Sui .
NATURE COMMUNICATIONS, 2013, 4
[79]   TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence [J].
Puig, Isabel ;
Tenbaum, Stephan P. ;
Chicote, Irene ;
Arques, Oriol ;
Martinez-Quintanilla, Jordi ;
Cuesta-Borras, Estefania ;
Ramirez, Lorena ;
Gonzalo, Pilar ;
Soto, Atenea ;
Aguilar, Susana ;
Eguizabal, Cristina ;
Caratu, Ginevra ;
Prat, Aleix ;
Argiles, Guillem ;
Landolfi, Stefania ;
Casanovas, Oriol ;
Serra, Violeta ;
Villanueva, Alberto ;
Arroyo, Alicia G. ;
Terracciano, Luigi ;
Nuciforo, Paolo ;
Seoane, Joan ;
Recio, Juan A. ;
Vivancos, Ana ;
Dienstmann, Rodrigo ;
Tabernero, Josep ;
Palmer, Hector G. .
JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (09) :3887-3905
[80]   The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation [J].
Raha, Debasish ;
Wilson, Timothy R. ;
Peng, Jing ;
Peterson, David ;
Yue, Peng ;
Evangelista, Marie ;
Wilson, Catherine ;
Merchant, Mark ;
Settleman, Jeff .
CANCER RESEARCH, 2014, 74 (13) :3579-3590